Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002399 · ClinicalTrials.gov registry record · Phase 2
A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
A Phase 2 study of HIV Infections and Candidiasis, Oral, sponsored by Schering-Plough.
- Completed
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT00002399: Completed Phase 2 study of HIV Infections and Candidiasis, Oral, sponsored by Schering-Plough.
NCT00002399 is a Phase 2 study of HIV Infections and Candidiasis, Oral that has completed, run by Schering-Plough. The registered enrollment target is 500 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002399, a Phase 2 study of HIV Infections and Candidiasis, Oral, has completed, sponsored by Schering-Plough.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.
Conditions Studied
Interventions
- DRUG Fluconazole
- DRUG Posaconazole
Study Locations (20)
Texas
- Univ of Texas Southwestern Med Ctr - Dallas
- Univ of Texas / Med School at Houston - Houston
- Univ of Texas Health Sciences Ctr - San Antonio
Other
- Centro de Micologia / Facultad de Medicina UBA - Buenos Aires
- Hosp Fernandez - Buenos Aires
- CHU Saint Pierre - Brussels
Florida
- Miami Veterans Administration Med Ctr - Miami
- Mercy Hosp - Miami
Georgia
- Ponce de Leon Med Ctr - Atlanta
- Med College of Georgia - Augusta
Arizona
- Tucson Veterans Administration Med Ctr - Tucson
Arkansas
- Northeast Arkansas Clinic - Jonesboro
Illinois
- Rush Med College / Rush Presbyterian - St Luke's Med Cen - Chicago
Indiana
- Wishard Hosp - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Phase | Phase 2 |
What the finished NCT00002399 record still lists
NCT00002399 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (12% higher).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Fluconazole is the first listed.
NCT00002399 names 20 study sites across 14 states, led by Texas, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT00002399 about?
NCT00002399 is a clinical study titled "A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients". The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.
What is the current status of trial NCT00002399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 500 participants.
What conditions does trial NCT00002399 study?
This clinical trial studies the following conditions: HIV Infections, Candidiasis, Oral.
What interventions are being tested in trial NCT00002399?
The interventions under investigation include: Fluconazole (DRUG), Posaconazole (DRUG).
Who is sponsoring clinical trial NCT00002399?
This trial is sponsored by Schering-Plough, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002399 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002399's enrollment target sits among peer trials
500 62nd of 542 higher than 479 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).